Arthneeti
RP

Remus Pharmaceuticals Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Remus Pharmaceuticals Ltd Q1 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book

Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹942
Market cap₹1.2K Cr
P/E31.2
Updated24 Sept 2026
Read5 min read

Based on Remus Pharmaceuticals Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY). EBITDA (Consolidated) for FY25: INR 457 Mn; FY24: INR 290 Mn; EBITDA margin FY25: 7.37%, FY24: 13.62% (margin decline YoY) - PAT (Consolidated) for FY25: INR 384 Mn; FY24: INR 243 Mn; PAT margin FY25: 6.19%, FY24: 11.41% (margin decline YoY) - Revenue From Operations (Consolidated) FY25: INR 6,204 Mn; FY24: INR 2,129 Mn (substantial YoY growth) - Standalone EBITDA for FY25: INR 260 Mn; FY24: INR 210 Mn; EBITDA margin FY25: 32.83%, FY24: 32.86% (stable margin) - Standalone PAT for FY25: INR 199 Mn; FY24: INR 166 Mn; PAT margin FY25: 25.13%, FY24: 25.98% (slight margin decline) - No explicit margin outlook or forward guidance on margins is stated in the presentation. Overall, while absolute EBITDA and PAT rose year-on-year robustly due to higher revenues, consolidated operating and PAT margins declined.

From Remus Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY).
  • Standalone Revenue from Operations for FY25 is INR 792 Mn, up from INR 639 Mn in FY24, around a 24% YoY growth.
  • B2C Revenue grew from INR 11 Mn in FY24 to INR 34 Mn in FY25, with product count increasing from 5 to 14.
  • B2B Revenue rose from INR 619 Mn in FY24 to INR 748 Mn in FY25, with number of products increasing from 204 to 222.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The provided investor presentation does not explicitly mention any capex, capacity expansion, or new plant/project details including amounts, status, or timelines. It focuses primarily on financials, business overview, market presence, product portfolio, regulatory and commercial strategies, shareholding, and forward-looking statements. No direct references to capital expenditure, expansion projects, or new facility developments are found in the disclosed slides.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any details regarding order book, order inflow, or pending orders. Specifically: - There is no mention of "order book," "order inflow," or "pending orders" in the disclosed financial or operational data. - The presentation focuses on registered products, revenue, shareholding pattern, financial highlights, market presence, and growth strategies.

2 more points management made on order book & pipeline

Continue your research

What Remus Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Shree Ganesh Remedies Ltd (Q1 FY26)

    Q1FY26 Revenue from Operations: ₹24.67 crores . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation — and how it

  • Anuh Pharma Ltd (Q1 FY26)

    Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma

  • Bharat Parenterals Ltd (Q1 FY26)

    Q1 FY 2026 Revenue from Operations (Consolidated):** ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Key investor presentation takeaways

  • Themis Medicare Ltd (Q1 FY26)

    Q1 FY26 Net Revenue: ₹97.58 Cr, down 20.7% year-on-year from ₹122.99 Cr in Q1 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q1 F

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Remus Pharmaceuticals Ltd Q1 FY26 results?

For FY25, Consolidated Operational Revenue is INR 6,204 Mn, up from INR 2,129 Mn in FY24, showing a significant increase (~191% YoY). EBITDA (Consolidated) for FY25: INR 457 Mn; FY24: INR 290 Mn; EBITDA margin FY25: 7.37%, FY24: 13.62% (margin decline YoY) - PAT (Consolidated) for FY25: INR 384 Mn; FY24: INR 243 Mn; PAT margin FY25: 6.19%, FY24: 11.41% (margin decline YoY) - Revenue From Operations (Consolidated) FY25: INR 6,204 Mn; FY24: INR 2,129 Mn (substantial YoY growth) - Standalone EBITDA for FY25: INR 260 Mn; FY24: INR 210 Mn; EBITDA margin FY25: 32.83%, FY24: 32.86% (stable margin) - Standalone PAT for FY25: INR 199 Mn; FY24: INR 166 Mn; PAT margin FY25: 25.13%, FY24: 25.98% (slight margin decline) - No explicit margin outlook or forward guidance on margins is stated in the presentation. Overall, while absolute EBITDA and PAT rose year-on-year robustly due to higher revenues, consolidated operating and PAT margins declined.

What is Remus Pharmaceuticals Ltd share price analysis?

Remus Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.2 with a market cap of ₹1,154 Cr. Investors should review the full earnings analysis for detailed insights.

Is Remus Pharmaceuticals Ltd planning capital expenditure?

The provided investor presentation does not explicitly mention any capex, capacity expansion, or new plant/project details including amounts, status, or timelines.

Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.